Key Developments: Smith & Nephew PLC (SNN.N)

SNN.N on New York Stock Exchange

34.35USD
20 Nov 2014
Price Change (% chg)

$0.07 (+0.20%)
Prev Close
$34.28
Open
$34.26
Day's High
$34.38
Day's Low
$34.05
Volume
31,375
Avg. Vol
63,263
52-wk High
$40.34
52-wk Low
$25.97

Search Stocks

Latest Key Developments (Source: Significant Developments)

Schweitzer-Mauduit International announces agreement to acquire assets from Smith & Nephew
Wednesday, 19 Nov 2014 

Schweitzer-Mauduit International Inc:Signs a definitive agreement to acquire certain assets from Smith & Nephew's Advanced Wound Management division.As part of the transaction, SWM will acquire SNN's Gilberdyke, UK facility, which will become part of DelStar's operations.Site produces films, nets and foams, which are sold as components for first-aid and wound dressings, and have a variety of other medical applications.Transaction is expected to close once customary closing conditions are met, which is anticipated in advance of year-end; terms of the transaction were not disclosed.Smith & Nephew is headquartered in London, UK.Transaction is expected to be accretive beginning in 2015.  Full Article

Smith & Nephew plc announces top-line results of HP802-247 Phase 3 study
Monday, 13 Oct 2014 

Smith & Nephew plc:Announces top line results from a Phase 3 study of HP802-247, a living cell spray-on therapy designed to work with the body's own cells to stimulate healing of venous leg ulcers.HP802-247 did not meet t he primary endpoint, namely a statistically improvement in healing over placebo, in a randomized, double-blind, vehicle-controlled study in North America.The result reported today announces full analysis of the efficacy data and study methodology is underway and will be completed in the coming months.A second Phase 3 study in the European Union, which is expected to report in 2016, will continue while the programme analysis is completed.  Full Article

Smith & Nephew Plc declares interim dividend
Friday, 1 Aug 2014 

Smith & Nephew Plc:Declares interim dividend of 2014 of $ 0.11 per ordinary share was declared by Board on July 31.Dividend is payable on Nov. 11 to shareholders whose names appear on register at close of business on Oct. 24.  Full Article

CORRECTION - Smith & Nephew Plc updates on FY 2014 outlook
Friday, 1 Aug 2014 

SENTENCE REMOVED - "Says that for FY 2014 it remains on track to meet guidance of mid teens revenue growth"....IN THE BODY (SEGMENTAL OUTLOOK).Smith & Nephew Plc:Says that for FY 2014 it remain confident in overall Group outlook.  Full Article

Smith & Nephew PLC announces appointment of new auditors
Friday, 11 Jul 2014 

Smith & Nephew PLC:Appointment of KPMG LLP (KPMG) as its auditor for year ending Dec .31, 2015, subject to approval by shareholders at 2015 AGM.  Full Article

Smith & Nephew PLC enters commercial agreement to bring robotic navigation to JOURNEY UNI Knee procedure
Thursday, 10 Jul 2014 

Smith & Nephew PLC:Says new commercial agreement with Blue Belt Technologies.Under this agreement, surgeons using Navio system will be able to implant Smith & Nephew's JOURNEY UNI partial knee.  Full Article

Smith & Nephew PLC completes acquisition of ArthroCare
Thursday, 29 May 2014 

Smith & Nephew PLC:Completes acquisition of ArthroCare Corporation.Purchase price was $48.25 per share paid in cash, translating into an enterprise value of about $1.5 bln.  Full Article

Smith & Nephew PLC fixes record and payment date for dividend
Friday, 25 Apr 2014 

Smith & Nephew PLC:As announced on Feb. 06, 2014, final dividend of $0.17 per share per ordinary share in respect of the year ended Dec. 31, 2013.Payable on May 07.Record date is April 22.  Full Article

Smith & Nephew plc launches JOURNEY II Cruciate Retaining natural-motion knee replacement
Wednesday, 12 Mar 2014 

Smith & Nephew plc:Launches JOURNEY II Cruciate Retaining (CR) knee replacement at American Academy of Orthopaedic Surgeons (AAOS) meeting in New Orleans.New implant extends JOURNEY II Total Knee System to procedures that preserve posterior cruciate ligament (PCL), which accounts for about half of all knee replacement procedures.  Full Article

Smith & Nephew and OrthoSensor to co-market VERASENSE Sensor Assisted Surgery with JOURNEY II and LEGION Total Knee Replacements
Monday, 10 Mar 2014 

Smith & Nephew PlC and OrthoSensor:Agreement that will enable surgeons to benefit from OrthoSensor's VERASENSE Sensor Assisted Surgery Technology for soft tissue balancing when implanting Smith & Nephew's JOURNEY II and LEGION Total Knee Systems.VERASENSE utilizes advanced sensor technologies to enable evidence-based surgical decisions regarding component position, limb alignment and soft tissue balance to optimize outcomes in total knee replacement.  Full Article

BRIEF-Smith & Nephew signs $800 mln private placement deal

* Fixed debt has an average rate of 3.1 pct and an average maturity of just over eight years Source text for Eikon: Further company coverage:

Search Stocks